Pharmacoeconomic challenges of molecular targeted therapy
نویسندگان
چکیده
منابع مشابه
Achievements and challenges of molecular targeted therapy in melanoma.
The treatment of melanoma has been revolutionized over the past decade with the development of effective molecular and immune targeted therapies. The great majority of patients with melanoma have mutations in oncogenes that predominantly drive signaling through the mitogen activated protein kinase (MAPK) pathway. Analytic tools have been developed that can effectively stratify patients into mol...
متن کاملTargeted molecular therapy of GBM.
Major advances in molecular biology, cellular biology and genomics have substantially improved our understanding of cancer. Now, these advances are being translated into therapy. Targeted therapy directed at specific molecular alterations is already creating a shift in the treatment of cancer patients. Glioblastoma (GBM), the most common brain cancer of adults, is highly suited for this new app...
متن کاملHepatotoxicity of molecular targeted therapy
A constant increase in occurrence of neoplasms is observed; hence new methods of therapy are being intensively researched. One of the methods of antineoplastic treatment is molecular targeted therapy, which aims to influence individual processes occurring in cells. Using this type of medications is associated with unwanted effects resulting from the treatment. Liver damage is a major adverse ef...
متن کاملPharmacoeconomic benefits of antihypertensive therapy.
BACKGROUND Effective blood pressure reduction reduces cardiovascular risk and prevents later complications. OBJECTIVE To consider the pharmacoeconomic benefits of antihypertensive therapy. SUMMARY Every managed care pharmacist should consider the balance of cost and benefit of antihypertensive therapies, ensuring that best treatment options for patients with the lowest cost to the health ca...
متن کاملMolecular Pathways Molecular Pathways: HER3 Targeted Therapy
The HER family of receptor tyrosine kinases, including EGF receptor (EGFR), HER2, HER3, and HER4, transduce growth-promoting signals in response to ligand binding to their extracellular domains (ECD). This family is deregulated in numerous cancers, withmutations in EGFR andHER2 often serving as "driver" events to activate key growth factor signaling pathways such as the RAS-ERK and PI3K-AKT pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2007
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2007.09.034